104 related articles for article (PubMed ID: 15820034)
1. Risks and ethics of gene transfer.
Reprod Biomed Online; 2005 Mar; 10(3):309. PubMed ID: 15820034
[No Abstract] [Full Text] [Related]
2. Basic research tries to decrease the risks of translational medicine.
Cavazzana-Calvo M
Gene Ther; 2009 Mar; 16(3):309-10. PubMed ID: 19279646
[No Abstract] [Full Text] [Related]
3. Ethics of cancer gene transfer clinical research.
Kimmelman J
Methods Mol Biol; 2009; 542():423-45. PubMed ID: 19565916
[TBL] [Abstract][Full Text] [Related]
4. Gene doping.
Harridge SD; Velloso CP
Essays Biochem; 2008; 44():125-38. PubMed ID: 18384287
[TBL] [Abstract][Full Text] [Related]
5. Assessing and communicating the risks and benefits of gene transfer clinical trials.
Kim SY
Curr Opin Mol Ther; 2006 Oct; 8(5):384-9. PubMed ID: 17078380
[TBL] [Abstract][Full Text] [Related]
6. Sarcoglycans take center stage in gene transfer therapy.
Müller OJ; Lochmüller H
Neurology; 2008 Jul; 71(4):234-5. PubMed ID: 18525030
[No Abstract] [Full Text] [Related]
7. The risks of germline gene transfer.
High KA
Hastings Cent Rep; 2003; 33(2):3. PubMed ID: 12760106
[No Abstract] [Full Text] [Related]
8. Therapeutic misconception in early phase gene transfer trials.
Henderson GE; Easter MM; Zimmer C; King NM; Davis AM; Rothschild BB; Churchill LR; Wilfond BS; Nelson DK
Soc Sci Med; 2006 Jan; 62(1):239-53. PubMed ID: 16000230
[TBL] [Abstract][Full Text] [Related]
9. Fetal gene therapy: opportunities and risks.
Wagner AM; Schoeberlein A; Surbek D
Adv Drug Deliv Rev; 2009 Aug; 61(10):813-21. PubMed ID: 19426772
[TBL] [Abstract][Full Text] [Related]
10. Safety assessment of intradiscal gene transfer: a pilot study.
Wallach CJ; Kim JS; Sobajima S; Lattermann C; Oxner WM; McFadden K; Robbins PD; Gilbertson LG; Kang JD
Spine J; 2006; 6(2):107-12. PubMed ID: 16517379
[TBL] [Abstract][Full Text] [Related]
11. Therapy on trial.
Hughes V
Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
[No Abstract] [Full Text] [Related]
12. Update on gene therapy approaches for cancer.
Wierdl M; Potter PM
Curr Hematol Rep; 2005 Jul; 4(4):294-9. PubMed ID: 16009044
[TBL] [Abstract][Full Text] [Related]
13. Accidental germ-line modifications through somatic cell gene therapies: some ethical considerations.
Kaplan JM; Roy I
Am J Bioeth; 2001; 1(4):W13. PubMed ID: 12862004
[TBL] [Abstract][Full Text] [Related]
14. Ethical considerations in clinical investigation: exploring relevance in haemophilia research.
DiMichele DM
Haemophilia; 2008 Jul; 14 Suppl 3():122-9. PubMed ID: 18510532
[TBL] [Abstract][Full Text] [Related]
15. Policy statement on the social, ethical and public awareness issues in gene therapy.
Gänsbacher B
J Gene Med; 2002; 4(6):687-91. PubMed ID: 12439860
[No Abstract] [Full Text] [Related]
16. The ethics of gene therapy.
Chan S; Harris J
Curr Opin Mol Ther; 2006 Oct; 8(5):377-83. PubMed ID: 17078379
[TBL] [Abstract][Full Text] [Related]
17. Staunch protections: the ethics of haemophilia gene transfer research.
Kimmelman J
Haemophilia; 2008 Jan; 14(1):5-14. PubMed ID: 18005150
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy: the good, the bad, and the ugly.
Raper SE
Surgery; 2005 May; 137(5):487-92. PubMed ID: 15855918
[No Abstract] [Full Text] [Related]
19. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials and SCID row: the ethics of phase 1 trials in the developing world.
Kimmelman J
Dev World Bioeth; 2007 Dec; 7(3):128-35. PubMed ID: 18021117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
